Celonic launches new GS-CHOvolution® Cell Line Expression System
GS-CHOvolution® is based on Revvity’s CHOSOURCETM expression platform and TnT transposon technology
Basel, Switzerland April 8, 2024 — Celonic has signed a commercial license agreement with Revvity for its CHOSOURCE™ expression platform and TnT transposon technology. The Revvity expression platform will be used in combination with Celonic’s expertise and workflows to enhance the cell line development of monoclonal antibodies (mAbs) and complex proteins.
GS-CHOvolution® is based on Revvity’s gene-edited Glutamine Synthetase (“GS”) knockout Chinese Hamster Ovary (CHO-K1) cGMP-compliant cell line and the TnT transposon technology to accelerate cell line development timelines and to streamline the selection of high expressing clones during cell line development. GS-CHOvolution’s expression platform is a well-established industry standard for biomanufacturing due to its ability to produce high yields of quality therapeutic proteins and is recognized by regulators as suitable for the manufacturing of monoclonal antibodies (mAbs) and complex proteins.
Biotech and pharma companies can use GS-CHOvolution’s® expression system through a simplified license fee model without royalties.
Dr. Samanta Cimitan, CEO Celonic Group, commented: “We are delighted to partner with Revvity to provide our customers a state-of-the-art GS expression platform with a track record of success which complements Celonic’s early phase offering. We are committed to bringing our customers of all sizes, expertise, agility and solutions to develop and manufacture life-improving drugs effectively and efficiently.”
Dr. Alan Fletcher, Revvity’s senior vice president, life sciences, stated: “Celonic and Revvity are likeminded organizations, we both seek to enable our customers and help advance the biotherapeutics of tomorrow. We are very pleased that Celonic has chosen the CHOSOURCE expression platform for their contract development and manufacturing services. Our well-established cGMP manufacturing CHO cell line has over 65 INDs filed globally and empowers companies to accelerate and streamline biotherapeutic development programs from DNA to clinical manufacturing. But what truly differentiates Revvity is our commitment to the evolution of our platforms and ongoing collaboration with our partners to achieve their current, as well as future, development and manufacturing needs.”
About Celonic:
Celonic is a “Pure Play” Biologics Contract Development Manufacturing Organization (CDMO) with significant expertise in the development and manufacturing of CHO based monoclonal antibodies and other molecules. Celonic’s roots trace back to 1982 as a spin-off of the Max Planck Institute in Germany. Today Celonic has a state-of-the-art Biologics Development and Innovation Center in Basel, Switzerland (headquarters), and clinical and commercial GMP manufacturing facilities in Heidelberg, Germany. At present, more than 500 highly qualified employees work at Celonic.
For more information, visit www.celonic.com
Follow @CelonicGroup on LinkedIn
Celonic Group Contact Details
Elisa Witt
Elisa.Witt@celonic.com
M: +41 76 588 67 59
About Revvity:
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.